TET3 and lip and oral cavity carcinoma: In laryngeal cancers, the frequency of hypermethylation was 54.5% for TET1, 15.9% for TET2, and 31.8% for TET3. Moreover, the frequency of promoter methylation in oropharyngeal cancers was 61.9% for TET1, 6.3% for TET2, and 25.4% for TET3. Among 69 cases of oral cancer, the frequency of hypermethylation was 58.0% for TET1, 21.7% for TET2, and 29.0% for TET3 (Figure 2A).